BioVision rev.11/17 For research use only

## Anti-CD11a (Efalizumab), Human IgG1 Antibody

**CATALOG NO:** A1089-200

ALTERNATIVE NAMES: LFA-1; integrin alpha L

**AMOUNT**: 200 μg

**IMMUNOGEN:** Efalizumab binds to CD11a, a subunit of leukocyte function

antigen-1 (LFA-1), which is expressed on all leukocytes.

**ISOTYPE /FORMAT:** Human IgG1, kappa

CLONALITY: Monoclonal

CLONE: hu1124

SPECIES REACTIVITY: Human

FORM: Liquid

**PURIFICATION:** Affinity purified using Protein A

**FORMULATION:** Supplied in PBS with preservative (0.02% Proclin 300)

STORAGE CONDITIONS: Store at 4°C for upto 3 months. For long term storage, aliquot and

freeze at -20°C. Avoid repeated freeze/defrost cycles.

**DESCRIPTION:** Recombinant monoclonal antibody to CD11a. Manufactured using

recombinant technology with variable regions (i.e. specificity) from

the therapeutic antibody hu1124 (Efalizumab).

BACKGROUND: Integrin alpha-L/beta-2 is a receptor for ICAM1, ICAM2, ICAM3

and ICAM4. It is involved in a variety of immune phenomena including leukocyte-endothelial cell interaction, cytotoxic T-cell mediated killing, and antibody dependent killing by granulocytes


and monocytes.

**APPLICATION:** Efalizumab binds to the LFA-1 alpha I domain blocking the ICAM-1

binding site via steric hindrance.

**REFERENCE:** Bauer *et al.* Population pharmacokinetics and pharmacodynamics

of the anti-CD11a antibody hu1124 in human subjects with psoriasis. J Pharmacokinet Biopharm. 1999 Aug; 27(4):397-420



Flow-cytometry using the anti-CD11a research biosimilar antibody Efalizumab: Human lymphocytes were stained with an isotype control or the rabbit-chimeric version of Efalizumab at a concentration of 1  $\mu$ g/ml for 30 mins at RT. After washing, bound antibody was detected using AF488 conjugated donkey anti-rabbit antibody and analyzed on a FACSCanto flow-cytometer.

## **RELATED PRODUCTS:**

- Anti-VEGF (Bevacizumab), humanized Antibody (Cat. No. A1045-100)
- Anti-HER2 (Trastuzumab), humanized Antibody (Cat. No. A1046-100)
- Anti-EGFR (Cetuximab), Chimeric Antibody (Cat. No. A1047-100)
- Anti-TNF-α (Adalimumab), humanized Antibody (Cat. No. A1048-100)
- Anti-CD20 (Rituximab), Chimeric Antibody (Cat. No. A1049-100)
- Anti-EGFR (Panitumumab), humanized antibody (Cat. No. A1050-100)
- Anti-OX40L (Oxelumab), Human IgG1 Antibody (Cat. No. A1088-200)
- Anti-EGFR (Matuzumab), Human IgG1 Antibody (Cat. No. A1090-200)
- Anti-CD4 (Clenoliximab), Human IgG4 Antibody (Cat. No. A1091-200)
- Anti-TNF alpha (Humicade), Human IgG4 Antibody (Cat. No. A1093-200)
- Anti-CD40L (Ruplizumab), Human IgG1 Antibody (Cat. No. A1094-200)
- Anti-Human Ephrin Type A receptor 2 (1C1), Human IgG1 Antibody (Cat. No. A1095)
- Anti-TNF alpha (Infliximab), Human IgG1 Antibody (Cat. No. A1097-200)
- Anti-IL-2R alpha (CD25) (Basiliximab), Human IgG1 Antibody (Cat. No. A1098-200)
- Anti-IL-2R alpha (Daclizumab), Human IgG1 Antibody (Cat. No. A1099-200)

FOR RESEARCH USE ONLY! Not to be used on humans.

